Clinical Trial News and Research

RSS

Use of antipsychotic drugs more common in boys than girls, research shows

Boys are more likely than girls to receive a prescription for antipsychotic medication regardless of age, researchers have found.

2 Jul 2015

Researchers complete phase 1 clinical trial of new drug for children suffering from neuroblastoma

Researchers at Spectrum Health Helen DeVos Children's Hospital have completed the first clinical trial of a new treatment for children suffering from neuroblastoma. In a clinical trial led by Giselle Sholler, MD, pediatric oncologist at Helen DeVos Children's Hospital and the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), DFMO, an investigational agent, showed minimal side effects with long-term survival of three patients.

2 Jul 2015

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the development of groundbreaking drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), announced today that Robert G. Miller, M.D., Director of the Forbes Norris MDA/ALS Research Center at Sutter Health's California Pacific Medical Center in San Francisco, has been awarded a grant from The ALS Association for $1.5 million to help fund a Phase 2 clinical study of the company's investigational therapy for ALS, NP001.

1 Jul 2015

Nuclea and Aelan partner to develop, commercialize novel biomarker tests using STEM cells as models

Nuclea Biotechnologies Inc. announced today that it is partnering with Aelan Cell Technologies Inc. (San Francisco, California) for the development, validation and commercialization of novel biomarker tests and companion diagnostics using human STEM cells as models.

1 Jul 2015

FAU awarded $2.1 million to examine effectiveness of antipsychotic medication for schizophrenia

Florida Atlantic University's Charles E. Schmidt College of Medicine was recently awarded a $2.1 million, two-year contract by Otsuka America Pharmaceutical Inc. to conduct a study to examine the effectiveness of an injectable long-acting antipsychotic medication for schizophrenia and its impact on 30-day hospital readmission rates.

1 Jul 2015

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to its fully human monoclonal antibody Aerucin for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

30 Jun 2015

Pinaverium offers quick relief from IBS symptoms

Pinaverium offers quick and effective relief of irritable bowel syndrome (IBS) symptoms, according to clinical trial results published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

30 Jun 2015

Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the successful results of the company's Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson's Disease (PD).

30 Jun 2015

BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that its CellDetect non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and other territories.

30 Jun 2015

First participant enrolled in RepliCel's RCT-01 Phase 1/2 clinical trial for treatment of chronic tendinosis

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections.

30 Jun 2015

BiondVax’s universal influenza vaccine meets safety and immunogenicity endpoints

BiondVax Pharmaceuticals Ltd. today announced positive preliminary results from its BVX-006 Phase II clinical trial of M-001, BiondVax's candidate for a universal influenza vaccine.

30 Jun 2015

Marken to deliver clinical trial drugs in Korea during MERS outbreak

Marken, the leading clinical trial logistics organization providing solutions and services to the life sciences industry, has been granted permission by the government to deliver the first direct to patient shipment of clinical drug product in Korea.

30 Jun 2015

New technique that mines Twitter data can help identify potentially dangerous drug interactions

A team of scientists has invented a new technique for discovering potentially dangerous drug interactions and unknown side-effects — before they show up in medical databases, like PubMed, or even before doctors and researchers have heard of them at all.

30 Jun 2015

Asterias Biotherapeutics added to Russell indexes

Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced that it has been added to the Russell 2000, Russell 3000, Russell Global and Russell Microcap indexes following Russell Investments' ("Russell") reconstitution of its comprehensive set of U.S. and global equity indexes after the close of the U.S. markets on June 26, 2015.

30 Jun 2015

BioClinica expands presence in Europe

BioClinica, Inc., the world's leading specialty clinical trial service provider, announced today the opening of new and expanded offices in London and Munich to better serve its growing client base in Europe.

From Clario 30 Jun 2015

Government of the Republic of Equatorial Guinea to sponsor development of Sanaria PfSPZ Vaccine for malaria

The Government of the Republic of Equatorial Guinea announced an agreement with industry partners, Marathon Oil Corporation, Noble Energy Inc. and AMPCO, to sponsor the clinical development of Sanaria PfSPZ Vaccine against malaria, including a series of clinical trials from 2015 until 2018.

30 Jun 2015

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers at Mayo Clinic, who conducted one of those clinical trials, believe they know why dasatinib failed — and what to do about it.

30 Jun 2015

SLU's Center for Vaccine Development receives $2.9 million to study new vaccine to combat TB

Saint Louis University's Center for Vaccine Development has received a $2.9 million award from the Bill & Melinda Gates Foundation to study a new tuberculosis vaccine.

30 Jun 2015

Axovant Sciences accepts two presentations at Alzheimer's Association International Conference 2015

Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the acceptance of two presentations at the Alzheimer's Association International Conference 2015 (AAIC) being held in Washington, D.C. from July 18-23, 2015.

30 Jun 2015

$FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease$

FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell’s Investigational New Drug application for the company’s lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease.

30 Jun 2015

Clinical Trial News and Research

Use of antipsychotic drugs more common in boys than girls, research shows

Researchers complete phase 1 clinical trial of new drug for children suffering from neuroblastoma

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Nuclea and Aelan partner to develop, commercialize novel biomarker tests using STEM cells as models

FAU awarded $2.1 million to examine effectiveness of antipsychotic medication for schizophrenia

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Pinaverium offers quick relief from IBS symptoms

Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

BioLight receives CE Mark approval for CellDetect bladder cancer test

First participant enrolled in RepliCel's RCT-01 Phase 1/2 clinical trial for treatment of chronic tendinosis

BiondVax’s universal influenza vaccine meets safety and immunogenicity endpoints

Marken to deliver clinical trial drugs in Korea during MERS outbreak

New technique that mines Twitter data can help identify potentially dangerous drug interactions

Asterias Biotherapeutics added to Russell indexes

BioClinica expands presence in Europe

Government of the Republic of Equatorial Guinea to sponsor development of Sanaria PfSPZ Vaccine for malaria

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

SLU's Center for Vaccine Development receives $2.9 million to study new vaccine to combat TB

Axovant Sciences accepts two presentations at Alzheimer's Association International Conference 2015

FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery